• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Vanda stock’s explosive rally may be more hype than substance

by February 23, 2026
written by February 23, 2026

Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA’s approval for its treatment of schizophrenia and bipolar I disorder.

The BYSANTI (milsaperidone) announcement is a welcome reprieve for VNDA that’s been under pressure this year as investors weighed “disappointing” Q4 earnings against a backdrop of clinical uncertainty.

However, while the “New Chemical Entity” (NCE) status and patent protection through 2044 offer a long-term runway, it’s reasonable to question whether Vanda Pharmaceuticals’ stock price rally is sustainable or a classic “sell the news” mirage.

VNDA shares may just be seeing a short squeeze

While the 44% pop makes for a glowing headline, the underlying mechanics suggest the rally may be driven more by technical desperation than fundamental shift.

Before the BYSANTI milestone, Vanda Pharmaceuticals was effectively a “penny stock” – at least for institutional investors – burdened by an alarming short interest of over 3.2 million shares.

With a relatively low float, the sudden influx of positive news likely “forced” short sellers to look for an exit, triggering a classic short squeeze.

Since such rallies are often fuelled by forced closing of bearish positions instead of long-term “buy and hold” conviction, they’re notoriously fragile.

As the squeeze exhausts, VNDA stock risks a rapid “mean reversion,” leaving retail investors who “chased the green” holding the bag on a cooling asset.

BYSANTI approval is more redundant than innovative

A closer look at the “innovation” behind BYSANTI suggests the enthusiasm might be overblown.

BYSANTI’s active mechanism is fundamentally tied to “iloperidone” – the same active ingredient found in Vanda’s existing drug, Fanapt. In fact, milsaperidone rapidly converts into iloperidone once ingested.

While the NCE status provides a fresh patent moat until 2044, the clinical reality is that BYSANTI is largely a “metabolic twin” of a drug that has been on the market for years.

This raises significant commercial hurdles; insurance payers are increasingly “resistant” to high-priced “new” versions of existing therapies.

And with the antipsychotic market saturated by low-cost generics, Vanda Pharmaceuticals shares face an uphill battle in proving BYSANTI offers enough clinical differentiation to justify premium pricing and gain meaningful market share.

How to play Vanda Pharmaceuticals stock at current levels

What’s also worth mentioning is that Vanda’s broader financial health remains a point of “serious concern” as well.

The company reported a staggering net loss in the fourth quarter of 2025, significantly missing analyst estimates with an EPS surprise of -84%.

Total revenues have shown signs of stagnation, and the company recently had to record a massive $113.7 million non-cash charge related to tax asset valuation allowances.

Furthermore, while the NCE status protects BYSANTI – Vanda Pharmaceuticals Inc’s other legacy products face the “patent cliff” that is currently ravaging the small-molecule sector in 2026.

With cash reserves dwindling by over $100 million in the past year, the company may be “forced” to dilute shareholders through a secondary offering to fund the Q3 2026 commercial launch, making the current VNDA share price a high-risk entry point for new investors.

The post Vanda stock’s explosive rally may be more hype than substance appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why is Nvidia stock soaring before Q4 earnings? Here’s $65.9B reason
next post
CrowdStrike stock: 3 simple reasons why AI can’t disrupt it

related articles

Meta, Microsoft earnings due next week: here’s what...

April 25, 2026

Evening digest: Google-Anthropic deal, DOJ drops probe against...

April 24, 2026

S&P 500, Nasdaq hit records; Dow slips as...

April 24, 2026

Nvidia replaced Intel in the Dow — today,...

April 24, 2026

X-Energy surges 36% in debut as $1B IPO...

April 24, 2026

Why is Skillz stock crashing despite major legal...

April 24, 2026

Lilly stock falls as Foundayo trails Novo’s Wegovy...

April 24, 2026

Palantir stock: Wyckoff Theory points to a dive...

April 24, 2026

Michael Burry just loaded up on Microsoft stock:...

April 24, 2026

Alphabet plans up to $40B investment in Anthropic:...

April 24, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Justice Sonia Sotomayor faces pressure to retire ahead of Trump taking office: report

    November 8, 2024
  • Cartel connection: Hezbollah and Iran exploit Maduro’s Venezuela for cocaine cash

    September 7, 2025
  • US thwarted near-catastrophic prison break of 6,000 ISIS fighters in Syria

    February 19, 2026
  • Barron Trump, celebrating 19th birthday, praised as ‘smart guy’ by his father

    March 20, 2025
  • DAVID MARCUS: 5 things New York Republicans need to hear from Andrew Cuomo

    October 22, 2025

Popular Posts

  • 1

    District judges’ orders blocking Trump agenda face hearing in top Senate committee

    April 2, 2025
  • 2

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    CoreWeave eyes $1.5B bond raise to ease debt load following lacklustre IPO: report

    May 9, 2025
  • 5

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024

Categories

  • Economy (829)
  • Editor's Pick (8,502)
  • Investing (2,060)
  • Stock (1,017)

Latest Posts

  • High-stakes US push for Ukraine peace meets hard limits in Moscow

    December 2, 2025
  • Trump has not directed admin to declassify Biden docs on health ‘cover-up’

    May 22, 2025
  • Brian Glenn reveals engagement to Rep. Marjorie Taylor Greene: ‘She said ‘yes”

    December 16, 2025

Recent Posts

  • There’s been a ‘meaningful shift’ in CEO confidence since Trump’s election, says Goldman’s Solomon

    January 15, 2025
  • Biden flip-flop on pardoning son Hunter is wildly unpopular with Americans, poll finds

    December 11, 2024
  • Trump taps FCC member Brendan Carr to lead agency: ‘Warrior for Free Speech’

    November 18, 2024

Editor’s Pick

  • What next for the Rolls-Royce share price as it falls into a correction?

    April 7, 2026
  • As inflation cools, Social Security could pay out a smaller COLA increase

    July 12, 2024
  • Iran spouts ‘propaganda’ from UN podium, calls on Middle East to unite behind Tehran

    September 25, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock